• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD.

作者信息

Benucci Maurizio, Damiani Arianna, Giannasi Gianfranco, Li Gobbi Francesca, Quartuccio Luca, Grossi Valentina, Infantino Maria, Manfredi Mariangela

机构信息

Rheumatology Unit, S Giovanni di Dio Hospital, Azienda USL-Toscana Centro, Florence, Italy

Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy.

出版信息

Ann Rheum Dis. 2023 Feb;82(2):e38. doi: 10.1136/annrheumdis-2020-218214. Epub 2020 Jul 6.

DOI:10.1136/annrheumdis-2020-218214
PMID:32632035
Abstract
摘要

相似文献

1
Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD.
Ann Rheum Dis. 2023 Feb;82(2):e38. doi: 10.1136/annrheumdis-2020-218214. Epub 2020 Jul 6.
2
Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy.38例接受改善病情抗风湿药治疗的风湿性疾病合并新型冠状病毒肺炎患者的特征与演变
Clin Rheumatol. 2021 Mar;40(3):1197-1199. doi: 10.1007/s10067-020-05510-9. Epub 2020 Nov 24.
3
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?COVID-19 疫情期间的风湿性疾病生物制剂：是敌是友？
RMD Open. 2021 Jan;7(1). doi: 10.1136/rmdopen-2020-001439.
4
Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani .对乔瓦尼所著《西班牙1037例接受生物制剂和JAK抑制剂治疗的风湿病患者中重症COVID-19的发病率》的回应
Ann Rheum Dis. 2022 Jul;81(7):e132. doi: 10.1136/annrheumdis-2020-218179. Epub 2020 Jun 25.
5
Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.西班牙一个由1037名接受生物制剂和JAK抑制剂治疗的风湿病患者组成的队列中重症新型冠状病毒肺炎的发病率。
Ann Rheum Dis. 2022 Jul;81(7):e131. doi: 10.1136/annrheumdis-2020-218152. Epub 2020 Jun 25.
6
Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry.在 COVID-19 大流行期间，炎症性风湿病患者的自我保护策略和健康行为：丹麦 DANBIO 注册中心随访的 12000 多名炎症性风湿病患者的结果和预测因素。
RMD Open. 2021 Jan;7(1). doi: 10.1136/rmdopen-2020-001505.
7
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.COVID-19 在接受靶向生物制剂和合成疾病修饰抗风湿药物治疗的成人和儿科风湿性疾病患者队列中的发病率。
Semin Arthritis Rheum. 2020 Aug;50(4):564-570. doi: 10.1016/j.semarthrit.2020.05.001. Epub 2020 May 16.
8
Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?靶向免疫抑制剂治疗的风湿性疾病患者 COVID-19 发病率：观察性数据能告诉我们什么？
Arthritis Rheumatol. 2020 Oct;72(10):1600-1606. doi: 10.1002/art.41388. Epub 2020 Sep 6.
9
Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques .对马克斯所著《风湿性疾病患者的COVID-19：真正的死亡风险是什么？》的回应
Ann Rheum Dis. 2022 Aug;81(8):e135. doi: 10.1136/annrheumdis-2020-218431. Epub 2020 Jul 13.
10
Rheumatic disease and COVID-19: epidemiology and outcomes.风湿性疾病与2019冠状病毒病：流行病学与结局
Nat Rev Rheumatol. 2021 Feb;17(2):71-72. doi: 10.1038/s41584-020-00562-2.

引用本文的文献

1
COVID-19 infection characteristics, risk factors and its potential impacts on Takayasu arteritis: a web-based survey in a large cohort.COVID-19 感染特征、危险因素及其对大动脉炎的潜在影响：一项基于网络的大型队列研究。
Front Immunol. 2024 Jan 8;14:1284168. doi: 10.3389/fimmu.2023.1284168. eCollection 2023.
2
[Not Available].[无可用内容]
Rev Rhum Ed Fr. 2022 Jun;89(4):405-411. doi: 10.1016/j.rhum.2022.04.010. Epub 2022 May 2.
3
Systematic assessment of the humoral response against SARS-CoV-2 in a French cohort of 283 patients with rheumatic diseases.
系统性评估法国 283 例风湿性疾病患者对 SARS-CoV-2 的体液免疫反应。
Joint Bone Spine. 2022 May;89(3):105312. doi: 10.1016/j.jbspin.2021.105312. Epub 2021 Dec 6.
4
Association between previous rheumatoid arthritis and COVID-19 and its severity: a nationwide cohort study in South Korea.既往类风湿关节炎与新型冠状病毒肺炎及其严重程度之间的关联：韩国一项全国性队列研究
BMJ Open. 2021 Oct 7;11(10):e054753. doi: 10.1136/bmjopen-2021-054753.
5
SARS-COV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study.风湿性疾病患者对 SARS-CoV-2 疫苗的接受度：一项横断面研究。
Hum Vaccin Immunother. 2021 Nov 2;17(11):4048-4056. doi: 10.1080/21645515.2021.1958611. Epub 2021 Aug 6.
6
Circulating Calprotectin as a Biomarker of COVID-19 Severity.循环钙卫蛋白作为新冠病毒疾病严重程度的生物标志物
Expert Rev Clin Immunol. 2021 May;17(5):431-443. doi: 10.1080/1744666X.2021.1905526. Epub 2021 Apr 13.
7
Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis.与普通人群相比，风湿性疾病患者感染新型冠状病毒肺炎的风险及临床结局：一项系统评价和荟萃分析。
Rheumatol Int. 2021 May;41(5):851-861. doi: 10.1007/s00296-021-04803-9. Epub 2021 Mar 9.
8
Inflammatory arthritis in patients with COVID-19.COVID-19 患者的炎症性关节炎。
Transl Res. 2021 Jun;232:49-59. doi: 10.1016/j.trsl.2021.02.010. Epub 2021 Feb 21.
9
Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data.COVID-19 患者风湿性疾病的临床结局：全球数据的系统评价和荟萃分析。
Autoimmun Rev. 2021 Apr;20(4):102778. doi: 10.1016/j.autrev.2021.102778. Epub 2021 Feb 18.
10
Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes.新型冠状病毒病 2019（COVID-19）在风湿性疾病患者中的流行病学和结局。
Best Pract Res Clin Rheumatol. 2021 Mar;35(1):101657. doi: 10.1016/j.berh.2020.101657. Epub 2020 Dec 23.